Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics is well positioned for growth due to its diverse pipeline of potential treatments for various serious disorders, its strong market share and payer coverage for its current product Korlym for Cushing's syndrome, and the potential for significant upside from its ongoing trials in oncology indications. The recent decision by the U.S. Court of Appeals in favor of generic competitors may lead to steeper discounts, but the company continues to hold a strong competitive advantage in the market. Risks include regulatory delays, clinical success, and legal and intellectual property challenges, but overall, the company has strong potential for success and a current attractive entry point for investors. The 12-month price target is $105 per diluted share, based on an NPV analysis, EV/sales analysis, and EV/earnings analysis, and the company also has promising long-term potential in the gynecologic oncology market with a potential total addressable market of ~60K patients.

Corcept Therapeutics is facing serious challenges in the competitive pharmaceutical industry, with ongoing lawsuits and potential generic forms of their flagship drug Korlym. The company's efforts to expand into other indications such as ovarian cancer with their drug relacorilant may face significant competition from established companies. Additionally, the recent subpoena from the US Attorney’s Office for theDistrict of New Jersey could result in further litigation and negatively impact the company's financials. These risks, combined with a steeper pricing discount for generic Korlym and an increased discount rate, have led to a reduction in our 12-month price target to $67 per diluted share. Overall, the company's outlook is negative due to these challenges and the potential threats to its key drugs in the market.